Cargando…

Hypomethylation of MIR‐378 5’‐flanking region predicts poor survival in young patients with myelodysplastic syndrome

BACKGROUND: Previous studies have disclosed up‐regulation of MIR‐378 in acute myeloid leukemia (AML), and might consequently affect the outcome of the patients. Correspondingly, hypomethylation of MIR‐378 was also identified in AML, particularly for FAB‐M2 subtype with t(8;21) chromosomal translocat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, De‐hong, Zhu, Xiao‐wen, Wen, Xiang‐mei, Zhang, Ying‐ying, Ma, Ji‐chun, Yao, Dong‐ming, Zhou, Jing‐dong, Guo, Hong, Wu, Peng‐fei, Zhang, Xing‐li, Qiu, Hong‐chun, Lin, Jiang, Qian, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978398/ https://www.ncbi.nlm.nih.gov/pubmed/31833222 http://dx.doi.org/10.1002/mgg3.1067

Ejemplares similares

Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome
por: Li, Xiao, et al.
Publicado: (2021)

The Interaction of miR-378i-Skp2 Regulates Cell Senescence in Diabetic Nephropathy
por: Tsai, Yi-Chun, et al.
Publicado: (2018)

Arsenic Disulfide Promoted Hypomethylation by Increasing DNA Methyltransferases Expression in Myelodysplastic Syndrome
por: Zhou, Qing-Bing, et al.
Publicado: (2020)

Hypomethylation of long interspersed nuclear element-1 promoter is associated with poor outcomes for curative resected hepatocellular carcinoma
por: Gao, Xu-dong, et al.
Publicado: (2014)

Management of myelodysplastic syndromes after failure of response to hypomethylating agents
por: Gil-Perez, Angela, et al.
Publicado: (2019)

Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
por: Montalban-Bravo, Guillermo, et al.
Publicado: (2018)

Serum microRNA-21 as a Potential Biomarker for Response to Hypomethylating Agents in Myelodysplastic Syndromes
por: Kim, Yundeok, et al.
Publicado: (2014)

P744: A REAL-WORLD STUDY OF MULTIPLE-CYCLE HYPOMETHYLATING AGENTS MONOTHERAPY IN MYELODYSPLASTIC SYNDROMES
por: Liu, Xiaozhen, et al.
Publicado: (2023)

Serum exosomal miR‐378 upregulation is associated with poor prognosis in non–small‐cell lung cancer patients
por: Zhang, Yan, et al.
Publicado: (2020)

Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome
por: Jung, Seung-Hyun, et al.
Publicado: (2016)

Oral Hypomethylating Agents for Myelodysplastic Syndromes: Highlights From SOHO 2020
Publicado: (2021)

A machine learning model of response to hypomethylating agents in myelodysplastic syndromes
por: Radakovich, Nathan, et al.
Publicado: (2022)

Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016)

Young woman with flank pain
por: Teijido, John Thomas, et al.
Publicado: (2020)

miR-378b Promotes Differentiation of Keratinocytes through NKX3.1
por: Wang, Xi-liang, et al.
Publicado: (2015)

Decreased transthyretin predicts a poor prognosis in primary myelodysplastic syndrome
por: Chen, Ying, et al.
Publicado: (2023)

Retrotransposition creates sloping shores: a graded influence of hypomethylated CpG islands on flanking CpG sites
por: Grandi, Fiorella C., et al.
Publicado: (2015)

Hypomethylation Causes MIR21 Overexpression in Tumors
por: Lu, Jun, et al.
Publicado: (2020)

Depicting the Implication of miR-378a in Cancers
por: Qin, Yuelan, et al.
Publicado: (2022)

Ergosterol Peroxide Isolated from Ganoderma lucidum Abolishes MicroRNA miR-378-Mediated Tumor Cells on Chemoresistance
por: Wu, Qing-Ping, et al.
Publicado: (2012)

No benefit of hypomethylating agents compared to supportive care for higher risk myelodysplastic syndrome
por: Sohn, Sang Kyun, et al.
Publicado: (2018)

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Wong, Kah Keng, et al.
Publicado: (2021)

Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia
por: Sorrentino, Vincent G., et al.
Publicado: (2021)

Response to Hypomethylating Agents in Myelodysplastic Syndrome Is Associated With Emergence of Novel TCR Clonotypes
por: Abbas, Hussein A., et al.
Publicado: (2021)

Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome
por: Grimm, Juliane, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis
por: Shou, Li-Hong, et al.
Publicado: (2017)

A Pilot Clinical Study to Investigate the Hypomethylating Properties of Freeze-dried Black Raspberries in Patients with Myelodysplastic Syndrome or Myeloproliferative Neoplasm
por: Dong, Athena, et al.
Publicado: (2022)

Hypomethylation of Interleukin-6 Promoter is Associated with the Risk of Coronary Heart Disease
por: Zuo, Hong-Peng, et al.
Publicado: (2016)

Hyperfibrinogenemia as a Poor Prognostic Indicator in Myelodysplastic Syndrome
por: Shi, Cong, et al.
Publicado: (2022)

Hepatic miR-378 modulates serum cholesterol levels by regulating hepatic bile acid synthesis
por: Sun, Chao, et al.
Publicado: (2021)

Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents
por: Lee, Sangmin, et al.
Publicado: (2022)

Synergistic Interactions between the Hypomethylating Agent Thio-Deoxycytidine and Venetoclax in Myelodysplastic Syndrome Cells
por: Hu, Xiaoyan, et al.
Publicado: (2023)

GPX3 methylation in bone marrow predicts adverse prognosis and leukemia transformation in myelodysplastic syndrome
por: Zhou, Jing‐Dong, et al.
Publicado: (2016)

hucMSC-derived exosomes attenuate colitis by regulating macrophage pyroptosis via the miR-378a-5p/NLRP3 axis
por: Cai, Xiu, et al.
Publicado: (2021)

miR194 hypomethylation regulates coronary artery disease pathogenesis
por: Duan, Lian, et al.
Publicado: (2022)

Hypomethylation of 111 Probes Predicts Poor Prognosis for Glioblastoma
por: Chen, Qi, et al.
Publicado: (2019)

Detection of SRSF2-P95 Mutation by High-Resolution Melting Curve Analysis and Its Effect on Prognosis in Myelodysplastic Syndrome
por: Lin, Jiang, et al.
Publicado: (2014)

miR-378-mediated glycolytic metabolism enriches the Pax7(Hi) subpopulation of satellite cells
por: Li, Hu, et al.
Publicado: (2022)

MiR-378a suppresses tenogenic differentiation and tendon repair by targeting at TGF-β2
por: Liu, Yang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_joqqm5a8t3o5i5qmscv332dda4